Is empagliflozin a sodium‑glucose co‑transporter‑2 (SGLT2) inhibitor?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, empagliflozin is an SGLT2 inhibitor

Empagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor that works by blocking glucose reabsorption in the kidney's proximal tubule, leading to increased urinary glucose excretion. 1

Mechanism of Action

Empagliflozin specifically inhibits SGLT2, the predominant transporter responsible for reabsorbing filtered glucose from the glomerular filtrate back into circulation. By blocking this transporter, empagliflozin:

  • Reduces renal glucose reabsorption
  • Lowers the renal threshold for glucose
  • Increases urinary glucose excretion (approximately 64-78 grams per day depending on dose) 1

Selectivity Profile

Among SGLT2 inhibitors, empagliflozin is one of the most selective for SGLT2 receptors 2. It demonstrates:

  • High specificity for SGLT2 over SGLT1 2
  • The highest SGLT2 specificity among all clinically used or currently tested SGLT2 inhibitors 3
  • Potent and selective inhibition of SGLT2 4, 5

Clinical Classification

Empagliflozin is consistently classified alongside other SGLT2 inhibitors (canagliflozin, dapagliflozin, ertugliflozin) in major clinical guidelines 6, 7, 8, 7. It shares the class characteristics of:

  • Insulin-independent glucose lowering
  • Cardiovascular and renal protective effects
  • Similar safety profile (genital mycotic infections, volume depletion risk)
  • Contraindication in severe renal impairment and dialysis 6, 8

The FDA-approved indications confirm its classification as an SGLT2 inhibitor for improving glycemic control in type 2 diabetes and reducing cardiovascular death risk in patients with established cardiovascular disease 6, 8, 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.